EP Patent

EP3313528B1 — Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer

Assigned to Bristol Myers Squibb Co · Expires 2021-08-04 · 5y expired

What this patent protects

Patent listed against chembl-chembl43452.

Drugs covered by this patent

Patent Metadata

Patent number
EP3313528B1
Jurisdiction
EP
Classification
—
Expires
2021-08-04
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.